Clinical trial · people

Thymogen (IM862): 8 of 25 kidney cancer patients had stable disease

Checked against the paper Clinical trialPublished by PepVault

The takeaway

In this trial, IM862 given alone was well tolerated but did not shrink spreading kidney cancer, and the team advised against testing it further this way in these patients.

Kind
Clinical trial
Studied in
People
Number studied
25
Published
2004
Journal
Br J Cancer

What they tested

The team tested whether IM862, the dipeptide also known as Thymogen, could shrink or control metastatic renal cell carcinoma (kidney cancer that has spread), and whether it was safe.

How the study was done

A prospective phase II trial with no comparison group in 25 adults with metastatic kidney cancer. Each person got IM862 intranasally (through the nose) at the trial's dose of 20 mg three times a day, in 8-week cycles.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking thymogen? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

None of the 25 patients had a significant objective response, meaning tumors did not shrink by a meaningful amount. 8 patients had stable disease (no growth) and 17 got worse while on treatment, with a median time to progression of 1.9 months and median survival of 7.9 months. Among 24 patients checked for side effects, none had grade 2 or 3 side effects tied to the drug. Blood levels of VEGF, a marker linked to blood vessel growth, fell significantly after 4 and 8 weeks.

What it doesn’t show

This was a small trial with no control arm, so it can't separate drug effects from the natural course of the disease. It tested only one dose and schedule, given alone, in one type of cancer.

The paper

Deplanque et al. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. Br J Cancer. 2004.

The compound

More studies on Thymogen

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking thymogen? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo